Premium
The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B‐rapidly accelerated fibrosarcoma‐mutated advanced melanoma
Author(s) -
Graf N.P.,
Koelblinger P.,
Galliker N.,
Conrad S.,
Barysch M.,
Mangana J.,
Dummer R.,
Cheng P.F.,
Goldinger S.M.
Publication year - 2019
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/jdv.15363
Subject(s) - medicine , dabrafenib , adverse effect , vemurafenib , trametinib , dermatology , melanoma , cancer research , mapk/erk pathway , metastatic melanoma , kinase , biology , microbiology and biotechnology
Abstract Background B‐rapidly accelerated fibrosarcoma (BRAF) inhibitor encorafenib alone and in combination with MEK inhibitor binimetinib improves survival in BRAF ‐mutated melanoma patients. So far, the range of cutaneous adverse events has been characterized only for established BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (trametinib, cobimetinib). Objective The aim of this study was to investigate cutaneous adverse events emerging in melanoma patients treated with encorafenib and binimetinib. Methods Patients treated with BRAF and MEK inhibitors in clinical trials at the University Hospital of Zurich were identified. Frequency and features of cutaneous adverse events as well as their management were assessed based on the prospectively collected clinical and histopathological data. The events emerging during encorafenib and/or binimetinib therapy were compared to other BRAF and MEK inhibitors at the institution and in the literature. Results The most frequent cutaneous adverse events observed in patients treated with encorafenib alone ( n = 24) were palmoplantar hyperkeratosis (54%), palmoplantar erythrodysesthesia (58%) and alopecia (46%). Drug‐induced papulopustular eruptions prevailed in patients with binimetinib monotherapy ( n = 25). The most frequent cutaneous adverse events in patients treated with encorafenib/binimetinib ( n = 49) were palmoplantar hyperkeratosis (10%). Conclusion Compared to data published for established BRAF i, encorafenib monotherapy showed less hyperproliferative cutaneous adverse events. In contrast, palmoplantar hyperkeratosis and palmoplantar erythrodysesthesia seem to occur more often. The combination of encorafenib and binimetinib is well tolerated and induces few cutaneous adverse events.